• Polyrizon began its first U.S. clinical study of NASARIX (PL-14), a drug-free nasal spray for seasonal allergic rhinitis.
• Results have not been presented; the trial is intended to generate future efficacy, safety, and tolerability data in patients.
• The study aims to show symptom relief by creating a physical nasal barrier to reduce allergen contact.
• Trial targets 120 adults across five U.S. sites, comparing NASARIX with a saline spray.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220833PRIMZONEFULLFEED9831318) on September 22, 2026, and is solely responsible for the information contained therein.